Irinotecan Loaded in Eluting Beads: Preclinical Assessment in a Rabbit VX2 Liver Tumor Model

Abstract

Compared with IV or IA, DEBIRI induces lower early serum levels of irinotecan, a high and prolonged intratumoral level of irinotecan, and a greater rate of tumor necrosis at 24 h. Further evaluation of the clinical benefit of DEBIRI is warranted.

Idarubicin-Loaded ONCOZENE Drug-Eluting Embolic Agents for Chemoembolization of Hepatocellular Carcinoma: In Vitro Loading and Release and In Vivo Pharmacokinetics

“…In a rabbit liver tumor model, it was shown after injection of 40 mm ONCOZENE DEE agents loaded with irinotecan that time at the drug maximum concentration (C max ) was prolonged (7). This time period was longer than that reported with DC Bead (8).…”

Safety and Efficacy Compared between Irinotecan-Loaded Microspheres HepaSphere and DC Bead in a Model of VX2 Liver Metastases in the Rabbit

“…Several microspheres loadable with IRI are now proposed: DC Bead ® (DC; Biocompatibles UK Ltd, London, United Kingdom), HepaSphere™ (HS; BioSphere Medical, Roissy-en-France, France), and TANDEM ® (CeloNova BioSciences, Newnan, Georgia). Preclinical trials evaluated the properties of the three products individually but not comparatively (12)(13)(14)(15)(16). One in vitro study suggested slight differences in the physical characteristics or elution properties of the different brands of microspheres (17).…”

Evaluation of the Plasmatic and Parenchymal Elution Kinetics of Two Different Irinotecan-Loaded Drug-Eluting Embolics in a Pig Model

“…This fast initial elution of irinotecan has been previously described for DEBIRI (16). In a rabbit VX2 liver tumor model, Rao et al (18) observed the highest irinotecan plasma concentration after 10 minutes. By contrast, Tanaka et al reported that TANDEM had a prolonged C max (24).…”

“…Irinotecan inhibits the DNA topoisomerase (13) and is a prodrug with the active metabolite SN-38 (14,15). Several experimental studies have investigated the pharmacokinetics of irinotecan after chemoembolization with DEBIRI (16)(17)(18)(19)(20). Plasma irinotecan levels were 70%-75% lower after embolization with drug-eluting embolic agents than after intra-arterial administration of irinotecan (19).…”